These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Jumex in the treatment of Alzheimer's disease]. Zarajczyk M Neurol Neurochir Pol; 1999; 33 Suppl 1():73-5. PubMed ID: 10404523 [No Abstract] [Full Text] [Related]
24. Clinical pharmacology of MAO inhibitors: safety and future. Yamada M; Yasuhara H Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896 [TBL] [Abstract][Full Text] [Related]
25. Dose regimen of deprenyl (selegiline) and platelet MAO activities. Oreland L; Johansson F; Ekstedt J Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150 [TBL] [Abstract][Full Text] [Related]
26. New mechanisms of action of irreversible monoamine oxidase type B inhibitors. Li XM; Juorio AV; Paterson IA; Boulton AA J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757 [No Abstract] [Full Text] [Related]
27. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940 [TBL] [Abstract][Full Text] [Related]
28. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations. Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285 [No Abstract] [Full Text] [Related]
29. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Henchcliffe C; Schumacher HC; Burgut FT Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338 [TBL] [Abstract][Full Text] [Related]
30. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Thomas T Neurobiol Aging; 2000; 21(2):343-8. PubMed ID: 10867219 [TBL] [Abstract][Full Text] [Related]
31. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119 [No Abstract] [Full Text] [Related]
32. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]
34. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Lew MF Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328 [TBL] [Abstract][Full Text] [Related]
35. Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients? Ames D; Ritchie C Int Psychogeriatr; 2007 Feb; 19(1):1-8. PubMed ID: 17310512 [No Abstract] [Full Text] [Related]
36. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Fernandez HH; Chen JJ Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750 [TBL] [Abstract][Full Text] [Related]
37. Is selegiline neuroprotective in Parkinson's disease? Gerlach M; Youdim MB; Riederer P J Neural Transm Suppl; 1994; 41():177-88. PubMed ID: 7931225 [TBL] [Abstract][Full Text] [Related]
38. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995. J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455 [No Abstract] [Full Text] [Related]
39. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Bortolato M; Chen K; Shih JC Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859 [TBL] [Abstract][Full Text] [Related]